[1] Asrani S K, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world[J]. J Hepatol,2019,70(1):151-171.
[2] Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18-The promises and challenges of a biomarker for chronic liver disease[J]. Aliment Pharmacol Ther,2009,30(11-12):1103-1109.
[3] Luedde T, Kaplowitz N, Schwabe R F. Cell death and cell death responses in liver disease: mechanisms and clinical relevance[J]. Gastroenterology,2014,147(4):765-783.
[4] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5): 947-957.
[5] Kaya E, Yilmaz Y. Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver[J]. J Clin Transl Hepatol,2022,10(2):329-338.
[6] Targher G, Corey K E, Byrne C D, et al. The complex link between NAFLD and type 2 diabetes mellitus-mechanisms and treatments[J]. Nat Rev Gastroenterol Hepatol,2021,18(9):599-612.
[7] Brouwers M C G J, Simons N, Stehouwer C D A,et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality[J]. Diabetologia,2020,63(2):253-260.
[8] Byrne C D, Targher G. NAFLD as a driver of chronic kidney disease[J]. J Hepatol,2020,72(4):785-801.
[9] Ding W, Fan J, Qin J. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systematic review and meta-analysis[J]. Int J Clin Exp Med,2015,8(1):322-333.
[10] Eslam M, Sanyal A J, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology,2020,158(7):1999-2014.
[11] 万艳,常剑波,白艳霞,等.血清学指标在非酒精性脂肪性肝病诊断中的意义[J]. 临床肝胆病杂志,2017,33(5):963-968.
[12] Mandelia C, Collyer E, Mansoor S, et al. Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease[J]. J Pediatr Gastroenterol Nutr,2016,63(2):181-187.
[13] Yang M, Xu D, Liu Y, et al. Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis[J]. PLoS One,2015,10(6):e0131664.
[14] Lee J, Vali Y, Boursier J, et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis[J]. PLoS One,2020,15(9):e0238717.
[15] Eguchi A, Iwasa M, Yamada M, et al. A new detection system for serum fragmented cytokeratin 18 as a biomarker reflecting histologic activities of human nonalcoholic steatohepatitis[J]. Hepatol Commun,2022,6(8):1987-1999.
[16] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版)[J].中华肝脏病杂志,2022,30(12):1309-1330.
[17] Pisano M B, Giadans C G, Flichman D M, et al. Viral hepatitis update: progress and perspectives[J]. World J Gastroenterol,2021,27(26):4018-4044.
[18] Bae C B, Kim S S, Ahn S J, et al. Caspase-cleaved fragments of cytokeratin-18 as a marker of inflammatory activity in chronic hepatitis B virus infection[J]. J Clin Virol,2013,58(4):641-646.
[19] Li J, Verhaar A P, Pan Q, et al. Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B[J]. Clin Exp Gastroenterol,2017,10:203-209.
[20] Asrani S K, Mellinger J, Arab J P, et al. Reducing the global burden of alcohol-associated liver disease: a blueprint for action[J]. Hepatology,2021,73(5):2039-2050.
[21] World Health Organization. World health statistics 2022: monitoring health for the SDGs, sustainable development goals[J]. World Health Organization,2022.
[22] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3): 188-194.
[23] Gonzalez-Quintela A, Abdulkader I, Campos J, et al. Serum levels of keratin-18 fragments[tissue polypeptide-specific antigen (TPS)] are correlated with hepatocyte apoptosis in alcoholic hepatitis[J]. Dig Dis Sci,2009,54(3):648-653.
[24] Mack C L, Adams D, Assis D N, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology,2020,72(2):671-722.
[25] 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗指南(2021)[J].中华肝脏病杂志,2022,30(5): 482-492.
[26] Derben F C, Engel B, Zachou K, et al. CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission[J]. Liver Int,2021,41(1):123-127.
[27] Korver S, Bowen J, Pearson K, et al. The application of cytokeratin-18 as a biomarker for drug-induced liver injury[J]. Arch Toxicol,2021,95(11):3435-3448.
[28] Tajima S, Yamamoto N, Masuda S. Clinical prospects of biomarkers for the early detection and/or prediction of organ injury associated with pharmacotherapy[J]. Biochem Pharmacol, 2019,170:113664.
[29] 中华医学会肝病学分会.胆汁淤积性肝病管理指南(2021)[J].中华肝脏病杂志,2022,30(3): 253-263.
[30] Masuoka H C, Vuppalanchi R, Deppe R, et al. Individuals with primary sclerosing cholangitis have elevated levels of biomarkers for apoptosis but not necrosis[J]. Dig Dis Sci, 2015, 60(12):3642-3646.
[31] Odenwald M A, Paul S. Viral hepatitis: past, present, and future[J]. World J Gastroenterol, 2022,28(14):1405-1429.
[32] 刘吉祥,谭礼让,金军.血清细胞角蛋白18裂解片段M30、前白蛋白和血小板衍生生长因子在乙型肝炎病毒感染相关疾病进展和预后中的价值[J]. 中国肝脏病杂志(电子版),2020,12(4):65-71.
[33] 周建,朱礼尧,冯伟广,等.细胞角蛋白18与合并2性型糖尿病的慢性丙型肝炎患者肝纤维化的相关性研究[J]. 胃肠病学和肝病学杂志,2018,27(9):1054-1057.
[34] Lavallard V J, Bonnafous S, Patouraux S, et al. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease[J]. PLoS One, 2011,6(3):e17599.
[35] Sekiguchi T, Umemura T, Fujimori N, et al. Serum cell death biomarkers for prediction of liver fibrosis and poor prognosis in primary biliary cirrhosis[J]. PLoS One, 2015, 10(6):e0131658.
[36] Ismail S A, El Saadany S, Ziada D H, et al. Cytokeratin-18 in diagnosis of HCC in patients with liver cirrhosis[J]. Asian Pac J Cancer Prev, 2017,18(4):1105-1111.
[37] Elalfy H, Besheer T, Arafa M M, et al. Caspase-cleaved cytokeratin 18 fragment M30 as a potential biomarker of macrovascular invasion in hepatocellular carcinoma[J]. J Gastrointest Cancer, 2018,49(3):260-267.
[38] Eguchi A, Iwasa M, Tamai Y, et al. The prognostic potential of fragmented CK18 serum levels in HCC patients reflecting disease progression and overall hepatocyte damage[J]. Front Oncol, 2022,12:993705.
[39] Zhu L, Jiang J, Zhai X, et al. Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study[J]. Liver Int, 2019, 39(1):70-80.
[40] 赵黎莉,李嘉,王春妍.细胞角蛋白 18 联合受控衰减参数对慢性乙肝合并代谢相关脂肪性肝病的诊断价值[J]. 实用器官移植电子杂志,2021,9(1):37-41. |
